How should nighttime drooling be managed in a 68-year-old patient with Parkinson's disease?

Management of Nighttime Drooling in Parkinson's Disease

For nighttime drooling (sialorrhea) in a 68-year-old Parkinson's patient, start with non-pharmacological interventions including sleeping position modification and environmental safety measures, then escalate to pharmacological treatment with botulinum toxin injections into salivary glands as the most effective option, or alternatively use anticholinergic medications if injections are not feasible.

Understanding the Problem

Nighttime drooling in Parkinson's disease affects approximately 27-29% of patients and results primarily from impaired swallowing and reduced oral motor control, not from excessive saliva production 1, 2. The saliva pools in the anterior mouth due to decreased automatic swallowing frequency during sleep. This can lead to aspiration pneumonia, skin irritation, and significant psychosocial distress 3, 4.

Nocturnal drooling often appears as a "pre-drooling" stage before progressing to diurnal (daytime) drooling, typically occurring later in disease progression (around 7-10 years disease duration) 1.

Step-by-Step Management Algorithm

First-Line: Non-Pharmacological Interventions

Environmental and positional modifications 5:

• Place a towel over the pillow to manage moisture
• Elevate the head of the bed to facilitate saliva drainage
• Encourage side-sleeping position rather than supine (back-sleeping)
• Ensure nasal breathing is not obstructed (address any nasal congestion)

Behavioral strategies:

• Chewing sugar-free gum during evening hours to promote swallowing 5
• Conscious swallowing exercises before bed
• Maintain good oral hygiene to reduce bacterial load

Second-Line: Pharmacological Treatment

Most Effective Option - Botulinum Toxin Injections:

Botulinum toxin type A (BoNT/A) injected bilaterally into the parotid and submandibular glands under ultrasound guidance is the most effective treatment for drooling in PD 6, 7, 2.

Key advantages of this approach:

• Reduces drooling consistently within 1-3 weeks
• Additionally improves swallowing function and dysphagia scores, not just drooling 6
• Effects last approximately 3-4 months, requiring repeat injections
• Minimal systemic side effects
• Particularly valuable when oral medications are contraindicated due to polypharmacy

The 2026 study by 6 demonstrated that BoNT/A injections improved both clinical dysphagia scores and neurophysiological swallowing parameters, suggesting the treatment facilitates oral floor and oropharyngeal motor coordination.

Alternative Pharmacological Options:

If botulinum toxin is unavailable or declined:

1. Anticholinergic medications (sublingual ipratropium spray preferred) 5, 7

   • Lower systemic anticholinergic burden than oral agents
   • Caution: Avoid atropine drops (lethal in overdose), hyoscine lozenges, and diphenhydramine as these worsen constipation 5
   • Monitor for cognitive effects in elderly patients

2. Amisulpride augmentation 5

   • Low adverse effect profile
   • Can be added to existing PD medications

Third-Line: Emerging Interventions

Neuromuscular Electrical Stimulation (NMES): NMES applied for 8 weeks showed improvement in drooling severity and frequency within 1-3 weeks 8. This is particularly useful for:

• Patients unable to tolerate new medications due to polypharmacy
• Those who have lost motivation for active rehabilitation
• Patients with multiple comorbidities

What NOT to Do

Avoid these common pitfalls:

• Do not assume increased saliva production is the cause—it's impaired clearance 2
• Avoid systemic anticholinergics with high cognitive burden (e.g., diphenhydramine, hyoscine) in elderly PD patients 5
• Do not use melatonin for drooling—while mentioned in sleep disorder guidelines 9, it has no established role in sialorrhea management
• Avoid omeprazole if treating concurrent reflux, as it induces CYP1A2 and lowers clozapine levels (though this is primarily relevant for psychiatric patients) 5

Monitoring and Follow-up

Assess severity using validated tools:

• Drooling Severity and Frequency Scale 5
• Toronto Nocturnal Hypersalivation Scale 5
• ROMP-saliva questionnaire 1

Monitor for complications:

• Aspiration risk (nocturnal choking episodes)
• Skin breakdown around mouth
• Psychosocial impact and quality of life
• Swallowing difficulties (often coexist with drooling) 6, 10

Special Considerations for This 68-Year-Old Patient

At 68 years with PD, this patient likely has moderate disease progression. Key assessment points:

• Evaluate for involuntary mouth opening (strongly associated with drooling) 1
• Check for concurrent dysphagia—present in 60-80% of PD patients and often coexists with drooling 11, 6
• Assess sleeping position and nasal breathing during night 1
• Review all medications for anticholinergic burden and constipation risk 11
• Screen for nutritional status, as PD patients are at 15-24% risk of malnutrition 11

The evidence strongly supports starting with positional/environmental modifications, then proceeding directly to botulinum toxin injections as the most effective intervention with the added benefit of improving swallowing function 6, 2.